A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2017
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 10 Jan 2017 Planned End Date changed from 1 Jul 2019 to 1 Jan 2020.
- 08 Nov 2016 Planned number of patients changed from 100 to 400.